nach oben

Esophagus

Erschienen in:

01.07.2015 | Case Report

A case of large cell neuroendocrine carcinoma of the esophagogastric junction

verfasst von: Minoru Fukuchi, Shinji Sakurai, Ritsuko Tsukagoshi, Hiroshi Naitoh, Hiroyuki Kuwano

Erschienen in: Esophagus | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine carcinoma of the upper gastrointestinal tract is an uncommon disease that manifests as a highly malignant tumor. We herein report a rare case of large cell neuroendocrine carcinoma of the esophagogastric junction treated with surgery and chemotherapy. A 65-year-old Japanese man was admitted to our hospital for treatment of a tumor of the esophagogastric junction detected by endoscopic examination. Biopsy specimens demonstrated large cell neuroendocrine carcinoma with highly frequent mitoses and positivity for synaptophysin, chromogranin A, and CD56. Computed tomography indicated at least three lymphadenopathies of the left and right cardiac nodes. We performed distal esophagectomy, total gastrectomy and pancreatosplenectomy, and subsequent S-1 adjuvant chemotherapy, but the patient died of liver metastasis 9 months after the surgery. Based on the outcome of the present case, this disease demands establishment of multimodal treatment that includes surgery and chemotherapy.

Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.PubMedCrossRef

Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyons: IARC; 2010. p. 13–4.

Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006;30:945–53.PubMedCrossRef

Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.PubMedCrossRef

Okamoto H, Fujishima F, Kasajima A, Miyata G, Onodera K, Kamei T, et al. A large cell neuroendocrine carcinoma of the esophagus (in japanese with english abstract). Jpn J Gastroenterol Surg. 2012;45:914–22.CrossRef

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef

Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37:949–59.PubMedCrossRef

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRef

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.PubMedCrossRef

10.

Veits L, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. Endoscopy. 2013;45:16–7.CrossRef

11.

Japan Esophageal Society. Japanese classification of esophageal cancer, 10th edition: parts II and III. Esophagus. 2009; 6: 71–94.

12.

Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–72.PubMedCrossRef

13.

Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998;122:1010–7.PubMed

14.

Namikawa T, Kobayashi M, Okabayashi T, Ozaki S, Nakamura S, Yamashita K, et al. Primary gastric small cell carcinoma: report of a case and review of the literature. Med Mol Morphol. 2005;38:256–61.PubMedCrossRef

15.

Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.PubMedCrossRef

16.

Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128:408–16.PubMedCrossRef

17.

Ishida M, Morita S, Saka M, Fukagawa T, Taniguchi H, Katai H. Metachronous liver metastasis from early gastric cancer. J Gastrointest Surg. 2012;16:837–41.PubMedCrossRef

18.

Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, et al. Recurrences and related characteristics of gastric cancer. Br J Cancer. 1996;74:975–9.PubMedCentralPubMedCrossRef

19.

Katai H, Maruyama K, Sasako M, Sano T, Okajima K, Kinoshita T, et al. Mode of recurrence after gastric cancer surgery. Dig Surg. 1994;11:99–103.CrossRef

20.

Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70–6.PubMedCrossRef

21.

Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg. 2004;26:183–8.PubMedCrossRef

22.

Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, National Comprehensive Cancer Network. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11:78–98.

23.

Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.PubMedCrossRef

24.

Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5:867–73.PubMedCrossRef

25.

Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005;129:977–83.PubMedCrossRef

26.

Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, On behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group and Lung Cancer Study Group of the Japan Clinical Oncology Group, et al. A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 2014;. doi:10.1093/jjco/hyt233.

27.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef

28.

Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14:161–5.PubMedCrossRef

Titel: A case of large cell neuroendocrine carcinoma of the esophagogastric junction
verfasst von: Minoru Fukuchi
Shinji Sakurai
Ritsuko Tsukagoshi
Hiroshi Naitoh
Hiroyuki Kuwano
Publikationsdatum: 01.07.2015
Verlag: Springer Japan
Erschienen in: Esophagus / Ausgabe 3/2015
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI: https://doi.org/10.1007/s10388-014-0443-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Successful salvage lymphadenectomy after stent grafting for aortic lymph node recurrence of thoracic esophageal carcinoma: a first case report

Utility of the over-the-scope-clip system for treating a large esophageal perforation

Associations between endoscopic findings and functional assessment via multichannel intraluminal impedance–pH monitoring in patients with non-erosive reflux disease refractory to proton-pump inhibitors

G-CSF-producing esophageal cancer with induction of intense bone marrow FDG uptake

Hyperbaric oxygen therapy for bleeding due to gastritis induced by chemoradiotherapy for regional recurrence of esophageal cancer post-radical esophagectomy

Esophageal cancer arising from esophageal mucous membrane pemphigoid